NF Trinity Capital’s Celgene CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
– Sell
-107,491
Closed -$6.89M – 49
2018
Q4
$6.89M Hold
107,491
– – 1.12% 24
2018
Q3
$9.6M Hold
107,491
– – 1.27% 22
2018
Q2
$8.54M Hold
107,491
– – 1.17% 21
2018
Q1
$9.6M Hold
107,491
– – 1.32% 18
2017
Q4
$11.2M Buy
107,491
+36,574
+52% +$4.13M 1.46% 16
2017
Q3
$10.3M Hold
70,917
– – 1.48% 16
2017
Q2
$9.21M Hold
70,917
– – 1.31% 18
2017
Q1
$8.82M Sell
70,917
-31,000
-30% -$3.71M 1.19% 19
2016
Q4
$11.8M Sell
101,917
-70,000
-41% -$7.8M 1.66% 16
2016
Q3
$18M Buy
171,917
+200
+0.1% +$21.6K 2% 14
2016
Q2
$16.9M Buy
171,717
+25,000
+17% +$2.59M 1.86% 17
2016
Q1
$14.7M Buy
146,717
+121,717
+487% +$12.5M 1.78% 17
2015
Q4
$2.99M Buy
+25,000
New +$2.89M 0.34% 39

Other funds holding CELG

NF Trinity Capital's CELG Position: Q1 2019 in Review

NF Trinity Capital sold out of Celgene (CELG) in Q1 2019, closing a stake of 107,491 shares — an estimated $6.89M sold.

NF Trinity Capital first reported a position in CELG in Q4 2015 and held it in 13 quarters. The position peaked at $18M in Q3 2016. 1,390 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

  • NF Trinity Capital reported no remaining Celgene position as of Q1 2019 after selling out during the quarter.
  • NF Trinity Capital sold 107,491 Celgene shares in Q1 2019, an estimated $6.89M.
  • NF Trinity Capital first reported a position in Celgene in Q4 2015 and held it in 13 quarters.
  • NF Trinity Capital's Celgene position peaked at $18M in Q3 2016.
  • 1,390 funds tracked by Wall St. Rank held Celgene as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.